Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficienc...( BUDAPEST Hungary and EXTON Pa. May 26...),Health

BUDAPEST, Hungary and EXTON, Pa., May 26 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of five abstracts relating to Cinryze(TM) (C1 esterase inhibitor [human]) therapy at the 6th Annual C1 Inhibitor Deficiency Workshop.

Cinryze was approved by the U.S. Food and Drug Administration in October 2008 for routine prophylaxis against hereditary angioedema (HAE) attacks in adults and adolescents. In February 2009, ViroPharma was granted priority review of a supplemental Biologics License Application for Cinryze for the treatment of acute attacks of HAE. If approved, Cinryze would be the first C1 esterase inhibitor available for the acute treatment for this condition. ViroPharma's PDUFA date for Cinryze in the acute setting is June 3, 2009.

"With the C1 Inhibitor Deficiency Workshop presentations focusing on items including HAE treatment considerations and the potential for subcutaneous infusion, among others, ViroPharma is demonstrating our commitment to meeting the needs of patients with C1 deficiency diseases today, and tomorrow," commented Glenn Tillotson, ViroPharma's senior director and head of Medical Affairs.

The following abstracts from studies supported by Lev Pharmaceuticals, a company acquired by ViroPharma Incorporated in October 2008, were presented:

Abstract book page 27: Prophylactic Therapy Considerations in Hereditary Angioedema

• In an abstract entitled, 'When Should Prophylactic Therapy be Considered for Hereditary Angioedema?', Dr. Tim Craig, et al. described how a literature review, guideline analysis from other countries, expert panel meeting, and consensus development were conducted in order to develop therapy considerations for prophylaxis of HAE in the U.S.;
• The
  '/>"/>